Given that the reference genome to map the sequence reads is usually of C57BL/6, do you care about the genetic background of the animal from which you get cells for your ChIP?
Unconfigured Ad
Collapse
X
-
I think the answer has to be "yes, it will make a difference". There might be some regions where your sample will differ too much from B6, and reads will fail to map, so you will miss that peak, which is exactly what you do not want.
You might try de novo asembly on unampped reads, and then figure out where those contigs align.
-
it will make a difference or sure. but i am in doubt whether it really matters and whether it is really a strong effect.
a) you will need quite some polymorphism to fail any read mapping in a peak region - given a peak base of maybe 200-400 bp.
b) it will also depend on the question you are asking: if you are interested in a particular locus you might have problem if a) applies. if you are interested in general phenomena, who cares if you miss one peak out of 15000?
anyone with real data regardings this issue?
Comment
-
Thanks mudshark. A friend has done ChIP-seq with input from C57BL/6 : DBA-2 mixed background and his reference genome has been that of C57BL/6. As you say, globally, there appears to be no problem. but you could be missing peaks.
unless someone has compared the same dataset, from a given genetic background, on two different reference genomes, we can't tell. I also wonder if any genome, other than that of BL/6 has a good coverage.
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
07-31-2026, 11:01 AM -
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 10:35 AM
|
0 responses
7 views
0 reactions
|
Last Post
by SEQadmin2
Today, 10:35 AM
|
||
|
Started by SEQadmin2, 08-06-2026, 07:41 AM
|
0 responses
24 views
0 reactions
|
Last Post
by SEQadmin2
08-06-2026, 07:41 AM
|
||
|
Started by SEQadmin2, 08-03-2026, 10:13 AM
|
0 responses
42 views
0 reactions
|
Last Post
by SEQadmin2
08-03-2026, 10:13 AM
|
||
|
Started by SEQadmin2, 07-31-2026, 02:55 AM
|
0 responses
47 views
0 reactions
|
Last Post
by SEQadmin2
07-31-2026, 02:55 AM
|
Comment